Osteoporosis News and Research

Latest Osteoporosis News and Research

Estrogen supplements do not suppress bone loss in postmenopausal women

Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University.

3 Sep 2009

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

Pacific Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of specialized reference laboratory and contract research services, today announced the Company's entry into a Loan and Security Agreement with Terry M. Giles, providing for a $4 million loan (the "Loan") to the Company.

2 Sep 2009

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

2 Sep 2009

Waist-hip ratio is a better of measure of obesity in older patients

Body mass index (BMI) readings may not be the best gauge of obesity in older adults, according to new research from UCLA endocrinologists and geriatricians. Instead, they say, the ratio of waist size to hip size may be a better indicator when it comes to those over 70.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

New technique developed for the treatment of cancer

A new paradigm in the way we look at cancer with important implications on how we treat it is about to be published in the British Journal of Cancer by Portuguese, Belgian and American researchers.

1 Sep 2009

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

31 Aug 2009

High dosage of ursodeoxycholic acid does not help PSC patients

A national team of researchers led by scientists at Mayo Clinic has found that a common treatment for primary sclerosing cholangitis, a chronic liver disease, is not helpful for patients, according to a study published this month in the journal Hepatology.

29 Aug 2009

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

28 Aug 2009

Forest Laboratories to host a conference call for discussing the results of Daxas Phase III clinical trials

Forest Laboratories, Inc., an international manufacturer and marketer of pharmaceutical products and Nycomed, a privately owned pharmaceutical company, will host a conference call at 7:15 AM EDT on Friday, August 28, 2009.

28 Aug 2009

Cardea and Optasia to collaborate on configuring their Vertebral Fracture Assessment software tools

Cardea Technology, Inc. and Optasia Medical Ltd., announce plans to collaborate and configure their software tools for Vertebral Fracture Assessment, a method for evaluating vertebral fractures from images on bone densitometers, to exchange information and create reports for the management of osteoporosis.

28 Aug 2009

Symptomless blood disorder MGUS not a precursor of serious diseases

A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

$Rates of hip fracture decline in Canada$

Rates of hip fracture decline in Canada

Standardized rates of hip fracture have steadily declined in Canada since 1985, with a more rapid decline between 1996 and 2005 and a more marked decrease among individuals age 55 to 64 years, according to a report in the August 26 issue of JAMA.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Osteoporosis News and Research

Latest Osteoporosis News and Research

Estrogen supplements do not suppress bone loss in postmenopausal women

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Waist-hip ratio is a better of measure of obesity in older patients

MammoSite ML radiation therapy system approved for breast cancer treatment

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

New technique developed for the treatment of cancer

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

High dosage of ursodeoxycholic acid does not help PSC patients

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories to host a conference call for discussing the results of Daxas Phase III clinical trials

Cardea and Optasia to collaborate on configuring their Vertebral Fracture Assessment software tools

Symptomless blood disorder MGUS not a precursor of serious diseases

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Rates of hip fracture decline in Canada

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Comparative effectiveness: Back surgery remains popular despite poor study results

UCLA finds link between high cholesterol and osteoporosis

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Osteoporosis News and Research

Latest Osteoporosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in